Please login to the form below

Not currently logged in
Email:
Password:

Mersana appoints Anna Protopapas as president and CEO

Joins from Millenium Pharmaceuticals

Anna ProtopapasMersana Therapeutics has named Anna Protopapas as president and CEO.

Protopapas joins the firm, which engineers antibody-drug conjugates (ADCs), from Takeda subsidiary Millennium Pharmaceuticals, where she held the same role.

Commenting on her new role, Protopapas said: “ADCs are a proven approach to cancer with two drugs on the market and over 30 in the clinic. Mersana's Fleximer-ADCs are a best-in-class approach, which overcomes the limitations of other ADC technologies.

“I am very encouraged by the results to date and look forward to working alongside the team at Mersana to translate the technology into important therapies for patients.”

Protopapas has expansive strategic leadership experience, with a demonstrated track record in the biopharma industry. Amongst her time in the sector, Protopapas has served as a member of the executive committee of Takeda, led Takeda's oncology business during her time at Millennium Pharmaceuticals and also held the role of executive VP of global business development.

Protopapas will additionally join Mersana's board of directors.

4th March 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics